Clinical Trial: Study of CM529D1 in Participants With Advanced Solid Tumors

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07893171) titled 'Study of CM529D1 in Participants With Advanced Solid Tumors' on Oct. 16.

Brief Summary: This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.

Study Start Date: Nov. 27

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: BIOLOGICAL: CM529D1

CM529D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.

BIOLOGICAL: CM529D1

CM529D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(R...